Investor Presentaiton slide image

Investor Presentaiton

33 Innovative Medicines EUR 235.1 million (-28.6%) NubeqaⓇsales more than doubled in 2023 - MEUR NubeqaⓇ sales booked by Orion¹ 70 60 50 40 30 20 10 10 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2023 • • • ORION Decline due to significant EUR 228 million upfront payment recorded in 2022 • Excluding the upfront payment, net sales more than doubled 2023 sales includes EUR 30 million NubeqaⓇ sales milestone NubeqaⓇ sales booked by Orion EUR 182.5 million (>100%) in 2023 Marinus received EU approval for ganaxolone² (brand name Ztalmy®) - Orion is focusing on making ganaxolone available for patients in Europe and has pricing and reimbursement processes planned or underway in Europe Product sales to Bayer 2022 Royalty ¹Orion's sales to Bayer for commercial use + royalties from Bayer Investor Presentation Orion Corporation 2 oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin- dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age. Treatment may be continued in patients 18 years of age and older.
View entire presentation